VRDN-001

Viridian’s lead product candidate, VRDN-001, is a differentiated monoclonal antibody targeting insulin-like growth factor-1 receptor (IGF-1R), a clinically and commercially validated target for the treatment of thyroid eye disease (TED). In preclinical studies, VRDN-001 was shown to be a full antagonist of IGF-1R, with more complete receptor blockade than other anti-IGF-1R antibodies, including the only currently approved TED therapy. Data from the initial dose cohorts of the Phase 2 portion of the ongoing trial established clinical proof-of-concept for VRDN-001 in patients with active TED. Preliminary data from the ongoing trial showed treatment with VRDN-001 led to reductions in proptosis, clinical activity score (CAS), and diplopia resolution. VRDN-001 was generally safe and well tolerated in the trial. The Company recently initiated its THRIVE Phase 3 trial in patients with active TED to support global marketing registration.

VRDN-001 is also being evaluated in Phase 2 trial cohorts in patients with chronic TED. Pending positive results, the Company plans to start its THRIVE-2 Phase 3 trial in patients with chronic TED.

Scientific publications for VRDN-001 can be found here.

VRDN-001 is an investigational therapy not approved for any use in any country.

VRDN-002

VRDN-002 is a distinct IGF-1R monoclonal antibody that incorporates half-life extension technology and is designed to support administration as a convenient, low volume, subcutaneous injection for the treatment of TED. Phase 1 data of VRDN-002 demonstrated an extended half-life up to 43 days.

Scientific publications for VRDN-002 can be found here.

VRDN-002 is an investigational therapy not approved for any use in any country.

VRDN-003

VRDN-003 is a monoclonal antibody that incorporates half-life extension technology into the sequence of VRDN-001, preserving the unique pharmacological attributes of VRDN-001 while adding the enhanced pharmacokinetics of VRDN-002. VRDN-003 is designed to support administration as a convenient, low volume, subcutaneous injection for the treatment of TED, and is in development as an alternative to VRDN-002.

VRDN-003 is an investigational therapy not approved for any use in any country.

VRDN-004

VRDN-004 is a discovery-stage therapeutic antibody program for an undisclosed rare disease.  We believe there is a significant opportunity to provide a more convenient, better performing product versus the only approved therapeutic in this disease. We are currently evaluating lead molecules generated by our antibody discovery and engineering platform.

VRDN-005

VRDN-005 is a preclinical program for an undisclosed autoimmune disease indication in which we believe patient care can be advanced with a new therapeutic monoclonal antibody.

VRDN-006

VRDN-006 is a preclinical program for an undisclosed autoimmune disease indication in which we believe patient care can be advanced with a new therapeutic monoclonal antibody.

Read about our approach to discovering and developing potential best-in-class medicines for patients with serious and rare diseases here.